CardioKinetix announces introduction of minimally invasive structural heart device in Asia

1 September 2013 (Last Updated September 1st, 2013 18:30)

CardioKinetix, a developer of catheter-based treatment methods for heart failure, has announced the first successful completion of heart failure surgery with Parachute ventricular partitioning device, its minimally invasive structural heart device, in Kuala Lumpur, Malaysia.

CardioKinetix, a developer of catheter-based treatment methods for heart failure, has announced the first successful completion of heart failure surgery with Parachute ventricular partitioning device, its minimally invasive structural heart device, in Kuala Lumpur, Malaysia.

The Parachute is a catheter based partitioning device deployed within the left ventricle through a small catheter inserted in the femoral artery of patients who have developed ischemic heart failure following a heart attack.

By partitioning the damaged muscle and isolating the non-functional muscle segment from the functional segment, the Parachute implant decreases the overall volume and restores a more normal geometry and function in the left ventricle.

The Parachute device helps in achieving better patient outcomes as it improves overall cardiac function and quality of life of patients.

"The Parachute device is an innovative new option that has demonstrated promising results in previous studies."

Institut Jantung Negara (National Heart Institute) in Kuala Lumpur, Malaysia CEO Dr Robaayah Zambahari said the institute is thrilled that the first Parachute procedure in Asia was performed in Kuala Lumpur.

"The Parachute device is an innovative new option that has demonstrated promising results in previous studies," Dr Zambahari said.

The Parachute device, which received CE Mark in 2011, is currently enrolling in the US pivotal trial, PARACHUTE IV.

CardioKinetix president and CEO Maria Sainz noted the expansion of the Parachute device into Asia is an important achievement for the company.

"Continuing to partner with leading clinicians and heart centres illustrates the promise the Parachute holds to bring a solution for the underserved heart failure patients around the world," Sainz said.

Approximately six million people are affected with heart failure in the US, leading to 1.1 million hospitalisations annually.

According to GlobalData estimates, left ventricular assist devices market in the US which was $361.6m in 2012 is expected grow at a CAGR of 15.1% to reach $967m by 2019.